Antiproliferative Effect of Somatostatin Analogs – Data Analyses and Clinical Applications in the Context of the CLARINET Study

Bencsiková, Beatrix

doi:10.14735/amko2016253

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For early stage PHNEC, surgical resection of liver tumor tissue or partial hepatectomy is the most common treatment [ 7 ], with a five-year survival of 74–78% [ 4 ]. Otherwise, treatment options are limited to liver transplantation, TACE, or administration of somatostatin [ 11 , 38 – 42 ]. Neither of our two cases was eligible for surgical resection of the tumor, and liver transplantation was not performed due to a lack of matched donor livers or financial concerns.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary hepatic neuroendocrine carcinoma: report of two cases and literature review

et al. 2018

View full text Add to dashboard Cite

Background Primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare. The diagnosis of PHNEC remains challenging—partly due to its rarity, and partly due to its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues. Case presentation We report two male PHNEC cases and discuss the diagnosis and treatment options. Both cases presented with abdominal pain; case two also presented with symptoms of jaundice. The initial diagnosis for both cases was poorly differentiated grade 3 small-cell neuroendocrine carcinoma, based on imaging characteristics and the pathology of liver biopsies. Final diagnoses of PHNEC were arrived at by ruling out non-hepatic origins. Case one presented with a large tumor in the right liver lobe, and the patient was treated with TACE. Case two presented with tumors in both liver lobes, invasions into the left branch of hepatic portal vein, and metastasis in the hepatic hilar lymph node. This patient was ineligible for TACE and was allergic to the somatostatin analogue octreotide. This limited treatment options to supportive therapies such as albumin supplementation for liver protection. Patient one and two died at 61 and 109 days, respectively, following initial hospital admission. Conclusions We diagnosed both cases with poorly differentiated grade 3 small-cell PHNEC through imaging characteristics, immunohistochemical staining of liver biopsies, and examinations to eliminate non-hepatic origins. Neither TACE nor liver protection appeared to significantly extend survival time of the two patients, suggesting these treatments may be inadequate to improve survival of patients with poorly differentiated grade 3 small-cell PHNEC. The prognosis of poorly differentiated grade 3 small-cell PHNEC is poor due to limited and ineffective treatment options.

show abstract

Section: Discussionmentioning

confidence: 99%

“…By interrupting the blood supply to the tumor while directly delivering chemotherapeutics, TACE inhibits tumor growth and extends survival. Somatostatin analogues, such as octreotide, can inhibit secretion of growth hormone by NECs and prevent tumor proliferation [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Primary hepatic neuroendocrine carcinoma: report of two cases and literature review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Those agents demonstrate antiproliferative action and reduce glucagon secretion. In the recent study lanreotide was proven to significantly prolong progression-free survival and is recommended for the treatment of patients with gastroenteropancreatic neuroendocrine tumours (grade 1 and 2) (Ki-67 proliferative index < 10%), regardless of the degree of liver involvement and the location of primary tumour [ 16 ]. Our patient complied with all of these criteria and lanreotide was used with good initial response and tolerability, which resulted in almost complete resolution of skin lesions.…”

mentioning

confidence: 99%